Characterising the nature of psychiatric disorders and patterns of antipsychotic medications prescribed in a psychiatric ward in a public hospital in Tasmania

IF 1.2 4区 医学 Q4 PSYCHIATRY Australasian Psychiatry Pub Date : 2024-09-14 DOI:10.1177/10398562241283156
Sharad Tamrakar, Antonio Mendoza Diaz, Adriana G Nevarez Flores, David Castle
{"title":"Characterising the nature of psychiatric disorders and patterns of antipsychotic medications prescribed in a psychiatric ward in a public hospital in Tasmania","authors":"Sharad Tamrakar, Antonio Mendoza Diaz, Adriana G Nevarez Flores, David Castle","doi":"10.1177/10398562241283156","DOIUrl":null,"url":null,"abstract":"ObjectiveWe present an evaluation of antipsychotic prescribing in an inpatient psychiatry ward in Hobart, Tasmania, to establish pattern of use, alignment with other psychiatric wards or centres and the recommendations in the Royal Australian and New Zealand College of Psychiatry Clinical Practice Guidelines, and to determine predictors of polypharmacy.MethodsA descriptive cross-sectional survey design was used. Data from 118 patients discharged from the Royal Hobart Hospital (RHH) Mental Health Inpatient Unit between 01/02/2021 to 01/08/2021 were evaluated.ResultsAntipsychotic polypharmacy (APP) was observed in 40% of patients. When low doses of adjunctive (‘PRN’) use of olanzapine and quetiapine were excluded, the APP proportion was 35%. APP was predicted by age and by a schizophrenia diagnosis. Long-acting injections (LAIs) were used in 46% of the patients. The most common LAI was risperidone (52%). Average daily dose of antipsychotic at the time of discharge was 529 mg chlorpromazine (CPZ) equivalents. High dose antipsychotics (more than 1000 mg CPZ equivalents per day) was observed in 13% of the patients.ConclusionsThe observed prescribing practice is consistent with other clinical settings. Antipsychotic prescribing practice should, however, continue to be monitored to ensure adherence to best practice guidelines.","PeriodicalId":8630,"journal":{"name":"Australasian Psychiatry","volume":"208 1","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10398562241283156","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

ObjectiveWe present an evaluation of antipsychotic prescribing in an inpatient psychiatry ward in Hobart, Tasmania, to establish pattern of use, alignment with other psychiatric wards or centres and the recommendations in the Royal Australian and New Zealand College of Psychiatry Clinical Practice Guidelines, and to determine predictors of polypharmacy.MethodsA descriptive cross-sectional survey design was used. Data from 118 patients discharged from the Royal Hobart Hospital (RHH) Mental Health Inpatient Unit between 01/02/2021 to 01/08/2021 were evaluated.ResultsAntipsychotic polypharmacy (APP) was observed in 40% of patients. When low doses of adjunctive (‘PRN’) use of olanzapine and quetiapine were excluded, the APP proportion was 35%. APP was predicted by age and by a schizophrenia diagnosis. Long-acting injections (LAIs) were used in 46% of the patients. The most common LAI was risperidone (52%). Average daily dose of antipsychotic at the time of discharge was 529 mg chlorpromazine (CPZ) equivalents. High dose antipsychotics (more than 1000 mg CPZ equivalents per day) was observed in 13% of the patients.ConclusionsThe observed prescribing practice is consistent with other clinical settings. Antipsychotic prescribing practice should, however, continue to be monitored to ensure adherence to best practice guidelines.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
分析塔斯马尼亚州一家公立医院精神科病房中精神疾病的性质和抗精神病药物处方的模式
目的我们对塔斯马尼亚州霍巴特市一家精神科住院病房的抗精神病药物处方进行了评估,以确定使用模式、与其他精神科病房或中心的一致性以及澳大利亚和新西兰皇家精神医学院临床实践指南中的建议,并确定多重用药的预测因素。对霍巴特皇家医院(RHH)精神健康住院部在2021年2月1日至2021年8月1日期间出院的118名患者的数据进行了评估。如果排除小剂量的奥氮平和喹硫平辅助用药("PRN"),APP比例为35%。年龄和精神分裂症诊断可预测 APP。46%的患者使用了长效注射剂(LAI)。最常见的长效注射剂是利培酮(52%)。出院时,抗精神病药物的日平均剂量为529毫克氯丙嗪(CPZ)当量。13%的患者使用大剂量抗精神病药物(每天超过1000毫克氯丙嗪当量)。然而,应继续对抗精神病药物处方进行监测,以确保其符合最佳实践指南。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Australasian Psychiatry
Australasian Psychiatry 医学-精神病学
CiteScore
2.80
自引率
5.60%
发文量
159
审稿时长
6-12 weeks
期刊介绍: Australasian Psychiatry is the bi-monthly journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP) that aims to promote the art of psychiatry and its maintenance of excellence in practice. The journal is peer-reviewed and accepts submissions, presented as original research; reviews; descriptions of innovative services; comments on policy, history, politics, economics, training, ethics and the Arts as they relate to mental health and mental health services; statements of opinion and letters. Book reviews are commissioned by the editor. A section of the journal provides information on RANZCP business and related matters.
期刊最新文献
Assessing the prevalence of personality pathology in Australian psychiatric emergency care centres: A feasibility study. Deprescribing antidepressants: An integral and neglected component of high-quality prescribing practice. The multiple 'faces' of burnout in clinical psychiatric practice. Augmenting clozapine with antipsychotics-Correspondence. A suicide in a Russian novel.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1